Eculizumab versus rituximab in generalised myasthenia gravis.

J Neurol Neurosurg Psychiatry · 2022 · PMC9016243 · PMID 35246490

Europe PMC DOI

hedged sentence

0.5100

closest p · 10.2× alpha

0.5100

boldest claim

The sentences

did not reach statistical significancep=0.510not close (p > 0.1)

During the 24-month observation period, nine patients experienced a MC in the rituximab group, while two patients deteriorated in the eculizumab group, which did not reach statistical significance (MC, n (%), rituximab 15 (15.8%) vs eculizumab 2 (10.0%), p=0.510).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.